<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648724</url>
  </required_header>
  <id_info>
    <org_study_id>Sym015-01</org_study_id>
    <secondary_id>2016-003912-11</secondary_id>
    <nct_id>NCT02648724</nct_id>
  </id_info>
  <brief_title>Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies</brief_title>
  <official_title>An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symphogen A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Symphogen A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first study to test Sym015 in humans. The primary purpose of this study is to
      see if Sym015 is safe and effective for patients with advanced solid tumors who do not have
      other available treatment options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first part of the study (Part 1, dose-escalation), Sym015 will be evaluated for
      safety and tolerability. Additionally, the recommended phase 2 dose (RP2D) will be
      determined. Sym015 will be given at different dose levels on an every second week (Q2W)
      dosing schedule. Each patient will be given one fixed dose level.

      In the second part of the study (Part 2, dose-expansion), two &quot;Basket Cohorts&quot; will be
      tested to see if Sym015 is effective in patients with solid tumors with a specific genetic
      abnormality called MET-amplification:

        -  Q2W Basket Cohort: Sym015 at the RP2D on a Q2W dosing schedule.

        -  Q3W Basket Cohort: Sym015 at the highest safe dose tested in Part 1 on an every third
           week (Q3W) dosing schedule.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Assess the safety and tolerability of Sym015 by occurrence of dose-limiting toxicities (DLT) measured during Cycle 1 of Sym015 administration on an every second week or every third week dosing schedule.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Confirmed objective antitumor response by RECIST v1.1</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine dosing regimen for Sym015 by evaluating the patient data for DLT's from Part 1 of the study.</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the anti-drug antibody profile of patients treated with Sym015 for immunogencity</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the action, and estimate, if feasible, the magnitude of biological activity by evaluating various biomarkers.</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in a dosing interval (i.e. from time zero (end of infusion) up to 336 hours or 504 hours depending on regimes).</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough)</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (TÂ½)</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last quantifiable concentration (Cz)</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose-Escalation (Phase 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym015 dose titration cohorts:
Dose Level 1: 6 mg/kg
Dose Level 2: 12 mg/kg
Dose Level 3: 18 mg/kg
Dose Level 4: 24 mg/kg
A substitute or additional dose level between the currently listed doses could potentially be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Q2W Basket Cohort (Phase 2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effective 04Nov2016: Patients with MET-amplified solid tumor malignancies will receive Sym015 as a loading dose of 18 mg/kg infused over 1.5 hours on C1/D1, followed by Q2W maintenance doses of 12 mg/kg infused over 1 hour beginning on C1/D15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Q3W Basket Cohort (Phase 2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MET-amplified solid tumor malignancies will receive the highest safest dose of Sym015 tested in Part 1 on a Q3W dosing schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym015</intervention_name>
    <description>Sym015 is a mixture of two monoclonal antibodies Hu9006 and Hu9338. Both antibodies are humanized IgG1, which specifically binds to non-overlapping epitopes in the extracellular domain of MET.</description>
    <arm_group_label>Part 1: Dose-Escalation (Phase 1a)</arm_group_label>
    <arm_group_label>Part 2: Q2W Basket Cohort (Phase 2a)</arm_group_label>
    <arm_group_label>Part 2: Q3W Basket Cohort (Phase 2a)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main inclusion criteria all patients, Part 1 and Part 2:

          -  Male or female, at least 18 years of age at the time of informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Life expectancy &gt;3 months assessed during Screening

          -  Documented (histologically- or cytologically-proven) solid tumor malignancy that is
             locally advanced or metastatic, and that is refractory to standard therapy or for
             which no standard therapy is available

          -  Tumor documented to be KRAS WT by local assessment (i.e. the tumor must express the
             KRAS WT, exon 2, 3 and 4)

        Additional main inclusion criteria applicable to Part 2, Basket Cohort patients ONLY:

          -  Measurable disease according to RECIST v1.1 that has been confirmed by computed
             tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle
             1/Day 1 (C1/D1)

          -  Confirmed MET-amplification

        Exclusion Criteria:

        Main exclusion criteria all patients, Part 1 and Part 2:

          -  Any antineoplastic agent (standard or investigational) within 4 weeks prior to C1/D1

          -  Immunosuppressive or systemic hormonal therapy within 2 weeks prior to C1/D1 with
             specified allowed exceptions

          -  Use of hematopoietic growth factors within 2 weeks prior to C1/D1

          -  Active second malignancy or history of another malignancy within the last 3 years,
             with specified allowed exceptions

          -  Central nervous system (CNS) malignancy including primary malignancies of the CNS,
             known CNS or leptomeningeal metastases not controlled by prior surgery or
             radiotherapy, or symptoms suggesting CNS involvement for which treatment is required

          -  Inadequate recovery from an acute toxicity associated with any prior antineoplastic
             therapy

          -  Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from
             any prior surgical procedure

          -  Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within
             1 month prior to C1/D1, unless adequately treated and stable

          -  Active uncontrolled bleeding or a known bleeding diathesis

          -  Significant cardiovascular disease or condition

          -  Abnormal hematologic, renal or hepatic function

          -  Any of the following within 2 weeks prior to C1/D1:

               -  Any serious or uncontrolled infection

               -  Any infection requiring parenteral antibiotics

               -  Unexplained fever &gt;38.0 Â°C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amita Patnaik, MD, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Texas Accelerated Research Therapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pia Pamperin, M.Sc. Pharm.</last_name>
    <phone>+45 4526 5050</phone>
    <email>ppa@symphogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan Horak, MD</last_name>
    <phone>+45 2055 2604</phone>
    <email>idh@symphogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Janku, MD, PhD</last_name>
      <email>fjanku@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Filip Janku, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@start.stoh.com</email>
    </contact>
    <investigator>
      <last_name>Amita Patnaik, MD, FRCP(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristoffer Staal Rohrberg, MD, PhD</last_name>
      <phone>+45 3545 6353</phone>
      <email>kristoffer.staal.rohrberg@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Kristoffer Staal Rohrberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Wha Moon, MD, PhD</last_name>
      <phone>+82 31 780 3436</phone>
      <email>ymoon@cha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong Wha Moon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Cheol Chung, MD, PhD</last_name>
      <phone>+82 22 228 8132</phone>
      <email>unchung8@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hyun Cheol Chung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <email>ykkang@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeeyun Lee, MD, PhD</last_name>
      <phone>+82 23 410 1779</phone>
      <email>jyunlee@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Jeeyun Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Cheul Oh, MD, PhD</last_name>
      <phone>+82 22 626 3060</phone>
      <email>sachoh@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Cheul Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>January 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor Malignancies</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
